A stemcell-based therapy that would be used to treat patients with brain or spinal injuries, or to stem the spread of HIV, tuberculosis and other illnesses.
It could also be used for cancer treatments and other serious diseases.
Michigan Technological University is working to develop stem cell-based therapies that would protect people from brain or spine injuries, spinal injuries or other serious illnesses.
Its stem cell therapies include a novel form of the virus-fighting peptide capsid protein called CRISPR-Cas9 that the University says is “the first and most important CRISpr-Cas10-based therapeutic”.
The stem cell therapy developed by the University is a novel type of CRISPr-Cas11-based virus-killing peptide that can kill viruses without triggering the cell’s immune response.
Its development is supported by a $50 million federal research program, called CART, led by the National Institutes of Health, which funds stem cell research.
Its work is supported, in part, by a grant from the Ford Foundation.
It is being led by MTH’s Joseph Sperber and the Michigan Technological Council’s Andrew Lees, both of whom are also in their late 40s.
They are members of the university’s faculty of engineering and of the School of Mechanical Engineering.
Their research focuses on developing a method to make CRIS-Cas7, a protein that can target viruses without disrupting their genomes, which is crucial to the virus’s survival.
The researchers developed a method using the same peptide to make a CRIS5 protein that is also part of the human immune system.
They also developed a novel, drug-resistant form of CRis5 that they say will be effective against the disease-causing virus, called the coronavirus.
The new CRIS7 protein is capable of attacking viruses at a much lower temperature and with a lower concentration of the protein than other CRIS proteins, they say.
The goal of the CRISs is to eliminate a virus that can spread easily through the human body and into other parts of the body, said Sperbers’ co-founder and professor of molecular and cell biology, Joe Lees.
It is not yet clear whether the researchers will be able to make it into clinical trials.
But their work has potential to save lives, they said.
The scientists have been able to isolate CRIS6 and CRIS9 from blood samples taken from more than 3,000 people.
CRISS6, they have found, kills the virus by killing the CRB proteins that normally bind to the surface of the viruses.CRIS9, which they believe has a more potent anti-viral effect, is the most promising, the researchers say.
Sperber said the team was not looking for a cure for the disease, but for a new treatment that could be used in a variety of conditions.
But they have not yet reached that goal.
“It’s not really clear that it’s going to be a cure, but we want to be able at some point to be successful in making a new therapeutic,” he said.
“We think that there are a lot of really interesting ways that we can go about this, and we hope that the research will help us do that.”
In the meantime, he said, his team will continue to test new ways of targeting the virus.
“This is a very exciting time,” he added.
“I think we’re getting close.”
Michigan Technology’s lead researcher, Michael Tompkins, said the new CRis7 peptide was the result of more than a decade of research.
“If we don’t get this out there as fast as we can, the virus will be out of the picture in the future,” he told News24.
“These new CRIs are going to make the virus less viable, but it will still be there.”
But if we can develop these things that we know will work, the next generation of CRIs will be much more effective.
“Lees said the research was a continuation of his group’s work.”
There is a lot more research that we’re doing now,” he explained.”
And this is just the beginning.